A detailed history of Black Rock Inc. transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 5,215,589 shares of SAGE stock, worth $30 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,215,589
Previous 4,892,162 6.61%
Holding current value
$30 Million
Previous $91.7 Million 38.22%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$10.58 - $17.9 $3.42 Million - $5.79 Million
323,427 Added 6.61%
5,215,589 $56.6 Million
Q1 2024

May 10, 2024

BUY
$18.62 - $26.95 $4.25 Million - $6.15 Million
228,262 Added 4.89%
4,892,162 $91.7 Million
Q4 2023

Feb 13, 2024

BUY
$17.1 - $22.26 $7.65 Million - $9.96 Million
447,305 Added 10.61%
4,663,900 $101 Million
Q3 2023

Nov 13, 2023

SELL
$16.75 - $48.98 $3.48 Million - $10.2 Million
-207,611 Reduced 4.69%
4,216,595 $86.8 Million
Q2 2023

Aug 11, 2023

SELL
$40.65 - $59.54 $20.6 Million - $30.1 Million
-505,580 Reduced 10.26%
4,424,206 $208 Million
Q1 2023

May 12, 2023

BUY
$37.27 - $46.57 $723,969 - $904,622
19,425 Added 0.4%
4,929,786 $207 Million
Q4 2022

Feb 13, 2023

BUY
$32.2 - $43.61 $2.84 Million - $3.85 Million
88,298 Added 1.83%
4,910,361 $187 Million
Q3 2022

Nov 14, 2022

BUY
$32.28 - $43.27 $18.7 Million - $25.1 Million
580,250 Added 13.68%
4,822,063 $189 Million
Q2 2022

Aug 12, 2022

BUY
$27.52 - $37.99 $40.9 Million - $56.5 Million
1,487,597 Added 54.01%
4,241,813 $137 Million
Q1 2022

May 12, 2022

SELL
$30.71 - $45.71 $774,536 - $1.15 Million
-25,221 Reduced 0.91%
2,754,216 $91.2 Million
Q4 2021

Feb 10, 2022

SELL
$37.06 - $47.11 $3.53 Million - $4.48 Million
-95,118 Reduced 3.31%
2,779,437 $118 Million
Q3 2021

Nov 09, 2021

BUY
$40.26 - $57.37 $968,534 - $1.38 Million
24,057 Added 0.84%
2,874,555 $127 Million
Q2 2021

Aug 11, 2021

BUY
$54.88 - $79.29 $156 Million - $226 Million
2,850,498 New
2,850,498 $162 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $342M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.